LT3448430T - Acetilcholinesterazės inhibitoriaus ir idalopirdino panaudojimas, skirtas parkinsono liga sergančių pacientų kritimų skaičiaus sumažinimui - Google Patents
Acetilcholinesterazės inhibitoriaus ir idalopirdino panaudojimas, skirtas parkinsono liga sergančių pacientų kritimų skaičiaus sumažinimuiInfo
- Publication number
- LT3448430T LT3448430T LTEPPCT/EP2017/059739T LTEP2017059739T LT3448430T LT 3448430 T LT3448430 T LT 3448430T LT EP2017059739 T LTEP2017059739 T LT EP2017059739T LT 3448430 T LT3448430 T LT 3448430T
- Authority
- LT
- Lithuania
- Prior art keywords
- idalopirdine
- parkinson
- disease patients
- acetylcholinesterase inhibitor
- reducing falls
- Prior art date
Links
- YBAWYTYNMZWMMJ-UHFFFAOYSA-N 2-(6-fluoro-1h-indol-3-yl)-n-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine Chemical compound FC(F)C(F)(F)COC1=CC=CC(CNCCC=2C3=CC=C(F)C=C3NC=2)=C1 YBAWYTYNMZWMMJ-UHFFFAOYSA-N 0.000 title 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- 229950005109 idalopirdine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600248 | 2016-04-26 | ||
| PCT/EP2017/059739 WO2017186686A1 (en) | 2016-04-26 | 2017-04-25 | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3448430T true LT3448430T (lt) | 2023-07-25 |
Family
ID=58632402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2017/059739T LT3448430T (lt) | 2016-04-26 | 2017-04-25 | Acetilcholinesterazės inhibitoriaus ir idalopirdino panaudojimas, skirtas parkinsono liga sergančių pacientų kritimų skaičiaus sumažinimui |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10383849B2 (lt) |
| EP (1) | EP3448430B1 (lt) |
| JP (1) | JP6992004B2 (lt) |
| KR (1) | KR102473545B1 (lt) |
| CN (3) | CN118806910A (lt) |
| AU (1) | AU2017256623B2 (lt) |
| BR (1) | BR112017026928B1 (lt) |
| CA (1) | CA3020557C (lt) |
| CL (1) | CL2018003013A1 (lt) |
| CY (1) | CY1126138T1 (lt) |
| DK (1) | DK3448430T3 (lt) |
| ES (1) | ES2949288T3 (lt) |
| FI (1) | FI3448430T3 (lt) |
| HR (1) | HRP20230693T8 (lt) |
| HU (1) | HUE062626T2 (lt) |
| IL (1) | IL262546B (lt) |
| LT (1) | LT3448430T (lt) |
| MX (1) | MX387444B (lt) |
| PL (1) | PL3448430T3 (lt) |
| PT (1) | PT3448430T (lt) |
| RS (1) | RS64307B1 (lt) |
| RU (1) | RU2742173C2 (lt) |
| SG (1) | SG11201809297UA (lt) |
| SI (1) | SI3448430T1 (lt) |
| SM (1) | SMT202300197T1 (lt) |
| TW (1) | TW201806621A (lt) |
| WO (1) | WO2017186686A1 (lt) |
| ZA (1) | ZA201806864B (lt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61704B1 (sr) | 2017-05-24 | 2021-05-31 | H Lundbeck As | Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele |
| EP3727043B1 (en) * | 2017-12-22 | 2026-06-10 | Golden Gait Biotech, S.L. | Nicotine for use in reducing frequency of falls in subjects with parkinson's disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818914D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| ES2566056T3 (es) | 2001-03-29 | 2016-04-08 | Eli Lilly And Company | N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6 |
| JP5180816B2 (ja) * | 2005-04-04 | 2013-04-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経変性疾患および認知症のためのジヒドロピリジン化合物 |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| JP2009541423A (ja) * | 2006-06-23 | 2009-11-26 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ |
| EP2254564A1 (en) * | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| RU2393158C1 (ru) * | 2008-10-06 | 2010-06-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
-
2017
- 2017-04-25 KR KR1020187030934A patent/KR102473545B1/ko active Active
- 2017-04-25 SI SI201731371T patent/SI3448430T1/sl unknown
- 2017-04-25 SG SG11201809297UA patent/SG11201809297UA/en unknown
- 2017-04-25 AU AU2017256623A patent/AU2017256623B2/en active Active
- 2017-04-25 HR HRP20230693TT patent/HRP20230693T8/hr unknown
- 2017-04-25 LT LTEPPCT/EP2017/059739T patent/LT3448430T/lt unknown
- 2017-04-25 ES ES17719255T patent/ES2949288T3/es active Active
- 2017-04-25 WO PCT/EP2017/059739 patent/WO2017186686A1/en not_active Ceased
- 2017-04-25 JP JP2018555748A patent/JP6992004B2/ja active Active
- 2017-04-25 CN CN202410836842.4A patent/CN118806910A/zh active Pending
- 2017-04-25 CN CN202410836839.2A patent/CN118806909A/zh active Pending
- 2017-04-25 BR BR112017026928-7A patent/BR112017026928B1/pt active IP Right Grant
- 2017-04-25 HU HUE17719255A patent/HUE062626T2/hu unknown
- 2017-04-25 RU RU2018135846A patent/RU2742173C2/ru active
- 2017-04-25 EP EP17719255.6A patent/EP3448430B1/en active Active
- 2017-04-25 RS RS20230489A patent/RS64307B1/sr unknown
- 2017-04-25 DK DK17719255.6T patent/DK3448430T3/da active
- 2017-04-25 US US15/496,159 patent/US10383849B2/en active Active
- 2017-04-25 MX MX2018013031A patent/MX387444B/es unknown
- 2017-04-25 SM SM20230197T patent/SMT202300197T1/it unknown
- 2017-04-25 FI FIEP17719255.6T patent/FI3448430T3/fi active
- 2017-04-25 CN CN201780025728.1A patent/CN109069650A/zh active Pending
- 2017-04-25 PT PT177192556T patent/PT3448430T/pt unknown
- 2017-04-25 PL PL17719255.6T patent/PL3448430T3/pl unknown
- 2017-04-25 CA CA3020557A patent/CA3020557C/en active Active
- 2017-04-25 TW TW106113760A patent/TW201806621A/zh unknown
-
2018
- 2018-10-15 ZA ZA2018/06864A patent/ZA201806864B/en unknown
- 2018-10-24 IL IL262546A patent/IL262546B/en unknown
- 2018-10-24 CL CL2018003013A patent/CL2018003013A1/es unknown
-
2023
- 2023-08-04 CY CY20231100395T patent/CY1126138T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281445A (en) | Therapeutic nanoparticles and methods for their use | |
| IL252943A0 (en) | Sunitinib formulations and methods of using them for the treatment of eye diseases | |
| IL246579B (en) | Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease | |
| PL4014976T3 (pl) | Aprocitentan do stosowania w leczeniu nadciśnienia tętniczego i chorób z nim związanych w połączeniu z walsartanem | |
| SI3676285T1 (sl) | Cepivo za uporabo pri profilaksi in/ali zdravljenju bolezni | |
| IL259862B (en) | Inhibitors of proton tyrosine kinase and methods of using them | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| PT3302454T (pt) | Composições para utilização no tratamento da doença de parkinson e distúrbios associados | |
| EP3261446A4 (en) | Methods and compositions for the treatment or prevention of parkinson's disease | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| ZA201903828B (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| ZA201806864B (en) | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients | |
| PL3137097T3 (pl) | Leczenie i profilaktyka choroby Alzheimera (AD) | |
| PL3137094T3 (pl) | Leczenie i profilaktyka choroby alzheimera (ad) | |
| SG11201510451RA (en) | Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders | |
| SG11201701618SA (en) | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders | |
| PL3137093T3 (pl) | Leczenie i profilaktyka choroby Alzheimera (AD) | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201317059D0 (en) | Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease |